Previous Article | Next Article 
Journal of Clinical Microbiology, May 1999, p. 1510-1517, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
New Enzyme Immunoassays for Sensitive Detection of Circulating
Candida albicans Mannan and Antimannan Antibodies: Useful
Combined Test for Diagnosis of Systemic Candidiasis
Boualem
Sendid,1
Marc
Tabouret,2
Jean Louis
Poirot,3
Daniel
Mathieu,4
Jeanine
Fruit,1 and
Daniel
Poulain1,*
Equipe INSERM 99-15, Laboratoire de Mycologie
Fondamentale et Appliquée, CH&U, Faculté de
Médecine, Pôle Recherche, F-59045
Lille,1 Sanofi Diagnostics Pasteur,
59114 Steenvoorde,2 Laboratoire de
Parasitologie-Mycologie, Hôpital Saint Antoine, 75012 Paris,3 and Service de
Réanimation Médicale et de Médecine Hyperbare,
Hôpital Calmette, Lille,4 France
Received 29 October 1998/Returned for modification 2 December
1998/Accepted 25 January 1999
 |
ABSTRACT |
Two standardized enzyme immunoassays for the serological diagnosis
of candidiasis were developed. The first one detects antimannan antibodies, while the second one detects mannan with a sensitivity of
0.1 ng/ml. These tests were applied to 162 serum samples
retrospectively selected from 43 patients with mycologically and
clinically proven candidiasis caused by Candida albicans.
Forty-three serum samples were positive for mannan, and 63 had
significant antibody levels. Strikingly, only five serum samples were
simultaneously positive by both tests. When the results were analyzed
per patient, 36 (84%) presented at least one serum positive by one
test. For 30 of them, positivity by one test was always associated with
negative results by the other test for any of the tested sera. For six patients whose sera were positive for either an antigen or an antibody
response, a balance between positivity by each test was evidenced by
kinetic analysis of sera drawn during the time course of the infection.
Controls consisted of 98 serum samples from healthy individuals, 93 serum samples from patients hospitalized in intensive care units, and
39 serum samples from patients with deep mycoses. The sensitivities and
specificities were 40 and 98% and 53 and 94% for mannanemia or
antibody detection, respectively. These values reached 80 and 93%,
respectively, when the results of both tests were combined. These
observations, which clearly demonstrate a disparity between circulation
of a given mannan catabolite and antimannan antibody response, suggest
that use of both enzyme immunoassays may be useful for the routine
diagnosis of candidiasis.
| |
INTRODUCTION |
Yeasts of the genus
Candida have been recognized as important agents of
hospital-acquired infections. They have become the fourth most common
isolate recovered from blood cultures in the United States
(23). Similarly, the rates of candidemia have increased
substantially in Europe as well (69, 70). Candidal infections occur on both medical and surgical services, but
approximately half of them occur in surgical intensive care units.
Depending on the hospital ward, the mortality rate attributable to
candidemia ranges from 40 to 60% (46, 73). Difficulties in
establishing an early and specific diagnosis of candidal infection are
among the recognized reasons for such high mortality rates. The
difficulties for clinical diagnosis lie in the absence of specific
clinical signs (1, 4). Difficulties for biological diagnosis
lie in the opportunistic character of yeasts. Their presence in
normally colonized body sites of immunocompromised patients does not
prove infection, and they are rarely isolated from infected deep organs or tissues including blood (43, 52, 55). Efforts have been made to find either antibodies against Candida albicans
molecules or Candida-derived molecules whose presence in
patient sera could indicate deep-tissue invasion. Tests have been
developed to detect C. albicans proteins (35, 39,
71), metabolites (62), DNA (5, 15, 63), and
polysaccharides. In this regard, a sensitive biochemical test for the
detection of glucan, a major structural polysaccharide of the cell
wall, has been made commercially available, and promising data from a
large number of centers have been documented with a large number of
serum samples from patients (29, 39, 40, 42). Like glucans,
mannans are major components of the C. albicans cell wall,
making up to 7% of the cell dry weight (26a). By contrast
to glucans, mannans are noncovalently bound at the cell wall surface
and are highly immunogenic (17). They correspond to a large
and complex repertoire of mannopyranose units linked by either 
-1,6,
-1,3, -1,2, or 
-1,2 linkages (61). Among these
units, oligomannose sequences corresponding to epitopes specific for
human and animal antibodies, either polyclonal or monoclonal, have been
identified; antibody recognition depends on both the type of linkage
connecting the mannose units and the length of the mannose chain
(17, 19, 22, 32, 47, 61, 65). These epitopes may also be
shared by the glycosidic moiety of a large number of different
mannoproteins or glycolipids, reinforcing the quantitatively major
character of mannose residues in C. albicans cells (64,
65). The use of mannan antigenemia (mannanemia) detection for the
immunodiagnosis of systemic candidiasis was suggested by Weiner and
Coats-Stephen (72) about two decades ago. Attempts to
improve the immunological detection of mannan involved the use of
immune complex dissociation by heating sera before performance of the
test and the use of monoclonal antibodies that react with defined
epitopes (21, 22, 53). These efforts resulted in
standardization and a high level of specificity. These tests, however,
like the commercially available Pastorex Candida, still lack
sensitivity due to the rapid clearance of the antigen from patients'
sera and the test format (latex agglutination) (21, 37, 39,
50).
In contrast to mannanemia detection, tests based on antimannan antibody
detection have been used less and less in the clinical diagnostic
mycology laboratory because they have been described both as poorly
specific and as poorly sensitive. The reasons for the poor specificity
and sensitivity could be attributed to the elevated antibody titers in
heavily colonized but uninfected hospitalized patients (44)
and the possible lack of antibody response in infected
immunocompromised patients (24). Although antimannan antibody and mannan antigenemia were used singly, to our knowledge, simultaneous assays for both components in the same sera have never
been performed. Thus, in this study, sera from patients with documented
candidiasis were tested for the presence of mannanemia and antimannan
antibodies. To facilitate the combined detection of both mannan and its
antibodies, we (i) developed a double-sandwich enzyme immunoassay (EIA)
using the monoclonal antibody used in the Pastorex Candida,
with increased sensitivity, and (ii) developed an EIA for the
simultaneous detection of antibodies. A total of 162 serum samples from
43 hospitalized patients were retrospectively selected because of the
presentation of clinical and mycological evidence of deep-seated
candidiasis caused by C. albicans and were assessed by the
methods that we developed for the presence of mannanemia and antimannan
antibodies. Our data demonstrate that the developed EIA format
increases the detection limit of mannan with increased sensitivity
without adversely affecting the test specificity. A striking finding in
this study is the observation that serum samples with a high mannanemia
response had a low (undetectable) levels of antimannan antibodies and
vice versa. This finding was consistent among patients in general and for a given patient during the time course of the disease.
| |
MATERIALS AND METHODS |
Patients.
Between January and December 1995, 162 serum
samples were retrospectively collected in two different university
hospitals from 43 patients (16 females and 27 males [mean age, 56 ± 17 years]) with proven candidiasis. The average number of serum
samples per patient in this group was 3.7 ± 2 (Table
1). The following criteria were applied
as retrospective selection rules when the laboratory and clinical files
were examined: (i) positive culture of specimens from normally sterile
sites (blood, bile, pericardial fluid, liver biopsy, drain, and wound
specimens) for C. albicans; (ii) availability of serum
samples obtained within a range of 1 week before and 2 weeks after
positive cultures; (iii) the presence of risk factors (cancer and
chemotherapy, abdominal surgery, AIDS, major health problems requiring
hospitalization in intensive care units [ICUs], and use of
broad-spectrum antibiotics, indwelling intravascular catheters, and
hyperalimentation; and (iv) the presence of an infectious syndrome
(namely, fever) that did not respond to antibacterial therapy but that
did respond to antifungal therapy.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Underlying diseases, culture data, and results of antigen
and antibody testing for patients with candidiasis
|
|
Control sera.
Three groups of control sera were included in
this study. (i) Group 1 comprised 93 serum specimens from 23 hospitalized patients (7 females and 16 males [mean age, 45 ± 12 years]) without evidence of invasive candidiasis. This group of
patients was enrolled in a prospective study conducted in an ICU of
Lille University Hospital for 6 months, the study was designed for the
assessment of risk factors for nosocomial candidiasis. These patients
were under clinical and mycological survey for periods ranging from 1 to 74 days (mean, 12 days). Samples of blood, oral swabs, urine, and
stools were collected biweekly. We selected 23 patients. For 19 patients Candida colonization was documented in at least one body site, but there was no proven, probable, or even suspected Candida tissue invasion. In four patients, candidal
colonization was not detected.
(ii) Group 2 consisted of 39 serum samples from patients with deep
mycoses not caused by Candida. Twenty-two serum samples were
retrospectively selected from 12 patients with invasive pulmonary aspergillosis (severe neutropenic patients with persistent fever, despite treatment with broad-spectrum antibacterial agents, and pulmonary infiltrates that developed on the chest roentgenogram). Invasive aspergillosis was also confirmed by the detection of Aspergillus galactomannan in sera. Three of 12 patients
included in this group were infected with human immunodeficiency virus (HIV). Thirteen patients (one serum sample from each patient) were
diagnosed with cryptococcal meningitis. Cryptococcal infection was
confirmed by isolation of Cryptococcus neoformans from
cerebrospinal fluid as well as detection of circulating antigen by the
Pastorex Crypto latex agglutination test (Sanofi Diagnostics Pasteur,
Marnes-la-Coquette, France). Among these patients, six were known to
have been infected with HIV for at least 3 months and two had undergone
kidney transplantation. Four serum samples were obtained from four
patients diagnosed with Pneumocystis carinii pneumonia.
These sera were retrospectively obtained from two patients who had
undergone bone marrow transplantation, one HIV-infected patient, and
one patient who had undergone kidney transplant surgery. All patients
were investigated for pulmonary disease, characterized by dyspnea,
cough, and fever and accompanied by abnormal chest radiographs. In each
case, the diagnosis of pneumonia was confirmed by the presence of
P. carinii cysts in bronchoalveolar lavages.
(iii) Group 3 consisted of 98 serum samples from 98 healthy blood
donors.
EIA detection of anti-C. albicans mannan antibodies
in human sera.
Microtiter plates were sensitized in an industrial
setting with C. albicans cell wall mannan. The mannan was
prepared from C. albicans VW32 grown in bioreactors under
standard conditions used for the chemical and immunochemical analysis
of this molecule (12). EIA was performed with BEP III
automate (Behring Laboratories, Paris, France). For the serological
diagnostic procedures already in use for Candida serology or
other antimannan detection tests (51), each set of tests
included a standard dilution which consisted of a serial twofold
dilution of a pool of patients' sera that strongly reacted with yeast
mannan. These standard dilutions were aliquoted and stored at 
30°C.
For individual sera, 100 µl of serum diluted 1/8,000 was applied to
each well, and the plate was incubated for 1 h at 37°C. After
washing, 100 µl of horseradish peroxidase-conjugated anti-human
immunoglobulins was then added, and the plates were incubated for
1 h at 37°C. After intensive washing, the reaction was revealed
by 30 min of incubation in darkness with 200 µl of
tetramethylbenzidine solution. The absorbance at a 
of 450/620 nm
was measured. The results were reported in arbitrary units (AU) in
relation to the results on the standard curve (Fig.
1).
View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
EIA detection of anti-C. albicans mannan
antibodies. The standard curve was obtained with serial dilutions of a
pool of sera strongly reacting with mannan extracted from C. albicans VW32. Standard reactivity of 100 AU was determined as the
dilution that gave the maximal absorbance at a of 450 nm.
|
|
By this test, preliminary experiments with 700 human serum specimens
showed that a satisfactory correlation was obtained between
immunofluorescence titers and EIA values (Spearman coefficient
= 0.83;
P = 0.0001) (data not shown). Ten AU corresponded
to an
immunofluorescence assay score of
400, which was considered
indicative
of candidiasis (
49).
Detection of mannanemia.
Two procedures were used to detect mannanemia.
The first method used the commercially available latex agglutination
test Pastorex
Candida (Sanofi Diagnostics Pasteur) and
was
performed according to the manufacturer's instructions. Three
hundred
microliters of patient sera was denatured with 100 µl
of EDTA
treatment solution, and the mixture was boiled for 3 min
and
centrifuged at 10,000 ×
g for 10 min. Forty
microliters of
supernatant was mixed in a plate well with 10 µl of
latex
particles.
The second method used to detect mannanemia was an EIA that we
developed by using the same monoclonal antibody (monoclonal
antibody
EBCA1) used to the sensitize latex particles in the Pastorex
Candida test. The minimal epitope of this monoclonal
antibody
has been shown to correspond to
-linked mannopentaose of
the
C. albicans VW32 mannan acid-stable domain; this epitope
is also
present on numerous
C. albicans mannoproteins
(
22). Microtiter
plates were sensitized with monoclonal
antibody EBCA1 in an industrial
setting. Fifty microliters of
supernatant, obtained from patient
serum and treated as described
above, was mixed in a plate well
with 50 µl of horseradish
peroxidase-conjugated EBCA1. After incubation
for 90 min at 37°C, the
plates were washed intensively and the
reaction was revealed by 30 min
of incubation in darkness with
200 µl of tetramethylbenzidine
solution. The optical density was
read at a
of 450/620 nm on a
PR2100 reader (Sanofi Diagnostics
Pasteur). Reactions were performed in
duplicate. Each experiment
included a calibration curve for a pool of
normal human sera supplemented
with concentrations of mannan of 0.1 to
27 ng/ml (Fig.
2).
View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
EIA detection of mannan extracted from C. albicans VW32 and spiked into a pool of negative sera. Standard
deviations calculated from duplicates in three different experiments
are noted by error bars.
|
|
Statistical analysis.
Data were analyzed with the SAS
program. Sensitivity, specificity, and predictive values were
calculated as described previously (54). The true-negative
population included blood donors, noninfected hospitalized patients,
and patients with deep mycoses not caused by a Candida sp.
| |
RESULTS |
Standardization of tests.
For each experiment for antimannan
antibody detection, individual sera are tested in duplicate. The
repeatability of the optical density (OD) values on a single microtiter
plate corresponded to a coefficient of variation (CV) of <10%. As
controls, each new set of experiments comprised sera from four patients
exhibiting graded antimannan antibody levels. The interseries
reproducibility obtained with these sera was examined after
transformation of the OD through the standard curve as described above.
This corresponded to a CV of <5% (n = 5). Concerning
circulating mannan antigen detection, preliminary experiments showed
that the sensitivity of detection was 0.1 ng/ml (the study was
performed with sequential dilutions of a negative serum supplemented
with 27 ng of mannan). In this study we considered 0.5 ng/ml to be the
cutoff level since 99% of the controls had mannanemia values that were
less than this value. The mannan concentrations in the tested sera were determined from the mean of the OD by using the sigmoid model curve
provided with the reader. The intra-assay reproducibility expressed as
the mean CV for the two control serum samples provided with the kit
(negative and positive) was 3.32% (n = 5). Interseries reproducibility for control sera and test samples mannan concentrations showed a CV of <4%.
Mannan concentrations and antimannan antibody titers in patient and
control sera.
Figure 3 shows the
results obtained with the 162 serum specimens drawn from the 43 patients with candidiasis tested by the EIA for the detection of both
antibodies and circulating mannanemia. Individual antigenemia values
(expressed in nanograms per milliliter) were plotted as a function of
the antimannan antibody response roughly distributed according to the
following four categories: A, the antibody response is weak or absent
(<10 AU); B, the antibody response is moderately above the cutoff
level (between 10 and 20 AU); C, the antibody response is medium
(between 20 and 40 AU); and D, the antibody response is strong (>40
AU). Sixty-three (37%) of the serum specimens had antibody titers that
exceeded 10 AU and only 43 (25%) displayed antigenemia values greater
than 0.5 ng/ml (25%). Strikingly, only 5 of 162 serum specimens
concomitantly had circulating mannan and significant antimannan
antibodies.
View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
Mannanemia in relation to antimannan antibody titers in
162 serum samples from 43 patients with systemic candidiasis.
Antimannan antibody titers (reported in AU) were divided into the
following four categories: A, 0 to 10 AU; B, 10 to 20 AU; C, 20 to 40 AU; D, >40 AU.
|
|
The results obtained for each of the 43 individual patients are
summarized in Table
1. Table
1 indicates the maximal antigenemia
and/or
antibody response obtained for at least one of the retrospectively
available serum samples. Patients have been classified into four
groups
according to the results observed by both tests. The first
group
(patients 1 to 7; 16%) corresponds to sera in which it was
not
possible to detect either antigens or antibodies; it is worthy
of note
that for three of the patients, only one sample was available.
In the
second group (patients 8 to 19; 28%), antigenemia was detected
without
evidence of an antibody response during the survey. In
the third group
(patients 20 to 37; 37%), no antigenemia was detectable
but a
significant antibody response was evidenced; for groups
2 and 3 which
represented 66% of the patients, the striking disparity,
i.e., lack of
detectable antigen in the presence of significant
amount of antibodies
and vice versa, is evident. This was also
observed for all sera drawn
from a single patient during the survey.
In the fourth group (patients
38 to 43; 13%), both antigenemia
and antibody detection tests were
positive. However, with the
exception of five serum specimens (two
drawn from patient 38 and
one each drawn from patients 40, 41, and 42),
we never observed
positivity by both tests for the same serum
sample.
The complementation of the antigen and antibody detection tests was
indeed evidenced when considering the kinetics of both
parameters with
sera drawn from individuals during the time course
of the disease.
Figure
4 shows the results corresponding
to the
mannanemia and antimannan antibody levels observed for patients
39 and 43 (see also Table
1). For patient 39 (Fig.
4a), a high
mannan
concentration was early detected in the serum available
1 week before
the isolation of
Candida from the patient's blood
(see
arrow). However, it became negative 5 days later and remained
under the
threshold limit thereafter (<0.5 ng/ml). At the time
of positive
antigenemia, the antibody response was negative and
sharply increased
to reach a maximum within 5 days, with a concomitant
decrease in
mannanemia. For patient 43 (Fig.
4b), 3 weeks prior
to the isolation of
C. albicans, the antibody response was around
the cutoff
point (11%). Then, the antibody response gradually
decreased during
the following 3 weeks. During the same period,
a strong antigenemia
peak was observed with a single serum sample
10 days before the
mycological isolation. The decrease in mannanemia
preceded the onset of
a strong antibody response concomitantly
with mycological detection.
View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Examples of kinetic evolution of antigenemia ( ) and
antimannan antibody response ( ) detected by EIA. Patients 39 (a) and
43 (b) had systemic candidiasis. The arrow marks the date of
mycological isolation of C. albicans from blood and a drain.
The curves are drawn by using the interpolate regression.
|
|
When a titer of 10 AU or more is considered to be a positive result by
the antimannan antibody detection test, 2% (2 of 98)
of healthy blood
donors, 8.6% (2 of 23) of patients from an ICU,
and 3.4% (1 of 29) of
patients with deep mycoses not caused by
Candida sp. had
positive results (Table
2). When a
threshold
concentration of 0.5 ng of mannan per ml of serum was used as
the limit for antigenemia, no positive results were detected for
sera
drawn from healthy blood donors, two of 29 (6.9%) patients
with deep
mycoses had positive results, and 1 of the 23 (4.3%)
ICU control
patients had a positive result.
The sensitivity, specificity, and positive and negative predictive
values calculated per patient for the Pastorex test and
the mannanemia
and antimannan antibody detection tests are shown
in Table
3. The sensitivity of the mannanemia
detection test
increased from 28 to 40% by using an EIA format instead
of a latex
agglutination assay format. This increase in sensitivity did
not
reduce the specificity. As can be seen from the analysis of
individual
data, the combined use of EIA detection of antimannan
antibodies
and EIA detection of mannanemia allowed the detection of
80% of
retrospectively mycologically proven deep
Candida
infections with
a specificity of 93%.
| |
DISCUSSION |
Numerous approaches for the serological diagnosis of candidiasis
have concentrated on the detection of C. albicans-derived molecules. These molecules were detected either on the basis of their
antigenicity or through biochemical-enzymatic procedures. More recent
progress has been made on the latter methods, and kits are commercially
available for the detection of arabinitol (62) and glucans
(29, 39, 40, 42), whereas PCR-based tests for
Candida DNA detection are routinely performed in some laboratories (5, 15, 63). Immunological detection of
C. albicans protein antigens of 47 and 48 kDa have
represented promising advances (35, 39, 71), but the use of
the commercially available assay (Directigen; Becton Dickinson) for the
detection of the 48-kDa vacuolar enolase has been limited by its cost.
In contrast, the Cand Tec latex agglutination test has been widely used
as the first commercially available antigen detection test (3, 19,
31, 67); the still unknown nature and function of the target
antigen have nonetheless impeded its further development. An
interesting feature of the serological detection of C. albicans-derived antigens in patient sera, in contrast to the
detection of nonimmunogenic molecules, is that the detected molecules
may elicit an antibody response in infected patients. Depending on the
pathophysiological importance of the antigen, joint consideration of
patient antigenemia and antibody response can provide insight into the
evolution of the infection. Such diagnostic strategies are commonly
used in virology for the serological survey of either HIV or hepatitis B virus infections. These methods involved the kinetics of the serum
antibody response to the p24, gp41, and gp120 of the hepatitis B
surface, core, and e antigens, respectively, for the detection of
antigenemia (14). Surprisingly, with the exception of the use of the approach for the detection of the 47-kDa antigen, which has
been shown both to circulate and to elicit protective antibodies (36), such an approach has never been applied to the
serological diagnosis of candidiasis. This is particularly true for the
mannan, the major immunogen of the C. albicans cell wall,
which for two decades has been shown to induce antibodies in humans and
to circulate in patients' sera (34). These diagnostic
approaches have considered mannan to be a single molecule, but they
failed to take into consideration its chemical and immunological
complexity. Within the mannan, a large number of chemically defined
sequences of mannose residues have been identified (61).
Depending on the type of linkage between the mannose residues and the
mannosyl chain length, mannan-derived oligomannosides have been shown
to be involved in such basic processes as inhibition of
lymphoproliferation (41), binding to epithelial cells and
macrophages (6, 7, 16, 33, 59), induction of cytokines and
arachidonic acid derivatives (2, 9), and induction of
protective or nonprotective antibodies in animal models
(19).
Polyclonal and then monoclonal antibodies have been used to detect
circulating mannan in patients' sera by either EIA (53), radioimmunoassay (72), latex agglutination (3, 18,
37), or coagglutination (30). Some of these epitopes
have been preliminarily characterized, as for monoclonal antibodies AF1
and 5B2, which have been shown to correspond to -1,2-linked
mannopyraosyl units of the mannan acid-labile domain (11,
50). In the present study, we have used monoclonal antibody
EBCA1, which is used to sensitize the latex particles involved in the
commercially available test Pastorex Candida. Recent studies
have shown that the monoclonal antibody EBCA1 minimal epitope was among
a mixture of mannopentaoses present in the mannan acid-stable domain:
an -1,2-linked isomer and an isomer in which the fifth mannose was
-1,6 linked to the reducing unit of manno--1,2-tetraose
(22). Therefore, monoclonal antibody EBCA1 epitopes fit with
the more general structure
Man1-(2Man1)n-2Man, (where n is
0), a type of mannopyranose chain that has been proposed to
correspond to antigenic factor 1 (27, 61), which is
ubiquitous in yeast species (66). The monoclonal antibody
EBCA1 epitope has also been shown to be expressed on the glycan moiety
of a large number of C. albicans mannoproteins which, if
released, can be detected in patient sera. Previous studies on antigen
detection with monoclonal antibody EBCA1 by the Pastorex latex
agglutination test have shown a good specificity but a poor sensitivity
(21, 39, 50). Therefore, we decided to increase the
sensitivity of the test by developing an EIA format instead of a latex
agglutination assay format. By using this method, the detection limit
has been improved up to 0.1 ng of mannan per ml. As expected, this
resulted in an increase in sensitivity which allowed us to detect
antigenemia in 40% of the patients, whereas with the Pastorex system
antigenemia could be detected in only 28% of the patients. This
increase in sensitivity was not detrimental to specificity since only 3 of the 150 control serum specimens were positive; none of them was from
healthy blood donors, 1 was drawn from a hospitalized colonized patient, and 2 were from patients infected with Aspergillus
fumigatus and C. neoformans, respectively. Although no
mycological evidence of candidiasis was found for these patients, the
possibility that they could be infected or coinfected with C. albicans could not be completely ruled out. When the sensitivity
of EIA is compared to that of Pastorex for each serum sample from
patients with candidiasis, in general, values lower than 1.5 ng/ml
failed to give a positive Pastorex test result. This resulted, however,
in a limited gain in overall sensitivity since 43 serum samples were
positive by EIA, whereas 35 were positive by Pastorex. Consideration of
these results for each serum sample is more disappointing than those for each patient, but this illustrates one of the major limitations of
mannanemia detection tests, which lies in the transient character of
antigen circulation (25, 52). As a consequence, sensitivity is a function of the number of serum samples available from each patient. In this study, sensitivity of mannanemia detection dropped from 40 to 11% if data for patients for whom only one serum sample was
available are considered. Several mechanisms have been proposed to
explain this observation, among which we can find the quick degradation
of mannose oligomers by serum mannosidases (10) or the
binding of the mannose oligomers to soluble serum proteins (mannose
binding protein C3) (20, 26, 60) or membranous receptors of
phagocytes (16, 33, 59). However, the present study
demonstrates that the detection of a given mannan catabolite in sera
from candidiasis patients is inversely correlated to the presence of
antimannan antibodies. Whether this phenomenon is restricted to the
epitope that was detected (22) (the epitope has structural
similarities to C. albicans mannan-derived O-linked oligomannosides that inhibit lymphocyte proliferation
[41]) or fits with the more general phenomenon of
antigen clearance by immune complexes remains to be established. These
results also led us, like others recently (68), to
reconsider the diagnostic value of antimannan antibody detection. We
have found a specificity of 94% and a sensitivity of 53% for the EIA
for antimannan antibody detection. It must be stressed that this
sensitivity was calculated by including data for patients for whom the
diagnosis was established by mannanemia detection. The combined tests
had a sensitivity and specificity of 80 and 93%, respectively. With
regard to the ability of both tests to diagnose C. albicans
infection early in the course of infection, conclusions can be drawn
only from data for the available sera due to the retrospective
character of this study. For 18 of the 43 patients included in the
study, at least one serum sample was available before mycological
evidence of infection was gained. When considering the results for
these sera, six patients presented with mannanemia (in the absence of significant antimannan antibody levels), nine patients presented with
significant antimannan antibody levels (in the absence of mannanemia),
and sera from the remaining three patients were negative by both tests.
Evidence of antigenemia and an antibody response was gained an average
of 6.2 and 7.3 days, respectively, before mycological isolation of
C. albicans. However, this study is limited to patients
infected with C. albicans only and patients infected with
non-C. albicans Candida species were not included.
Preliminary results obtained with sera from patients infected with
Candida glabrata, Candida tropicalis,
Candida parapsilosis, and Candida krusei which,
together with C. albicans, account for more than 95% of
hospital Candida infections, are encouraging. This
observation is not surprising since these different species of the
Candida genus share both the EBCA1 epitope distribution on
their mannan and mannoproteins (22) (for antigen detection
tests) and a high level of cross-antigenic mannan reactivity (for
antibody detection tests) (61). This study has shown that
the combined performances of antigen and antibody detection by these
tests were similar, irrespective of the immunosuppression status of the
patient and the service. Evaluation of the utility of both tests in
prospective studies enrolling large numbers of patients at risk for
candidiasis (73) is necessary.
| |
ACKNOWLEDGMENTS |
We are grateful to Mahmoud A. Ghannoum and Donald Mackenzie for
helpful suggestions on the manuscript. We thank also Gabriel Reboux
(Besançon) for providing the sera from patients with cryptococcal meningitis and Laurence Richard and Nadine François for expert technical assistance.
This work was supported by a grant from the "Programme Hospitalier de
Recherche Clinique du Ministère des Affaires Sociales, de la
Santé et de la Ville."
| |
FOOTNOTES |
*
Corresponding author. Mailing address: Equipe INSERM
99-15, Laboratoire de Mycologie Fondamentale et Appliquée, CH&U,
Faculté de Médecine, Pôle Recherche, Place de Verdun,
59045 Lille Cedex, France. Phone: 33 03 20 44 55 77. Fax: 33 03 20 44 42 64. E-mail: dan_poulain{at}compuserve.com.
| |
REFERENCES |
| 1.
|
Armstrong, D.
1989.
Problems in management of opportunistic fungal diseases.
Rev. Infect. Dis.
11(Suppl. 7):1591-1599.
|
| 2.
|
Ashman, R. B., and J. M. Papadimitriou.
1995.
Production and function of cytokines in natural and acquired immunity to Candida albicans infection.
Microbiol. Rev.
59:646-672[Abstract/Free Full Text].
|
| 3.
|
Bailey, J. W.,
E. Sada,
C. Brass, and J. E. Bennett.
1985.
Diagnosis of systemic candidiasis by latex agglutination for serum antigen.
J. Clin. Microbiol.
21:749-752[Abstract/Free Full Text].
|
| 4.
|
Bodey, G. P. (ed.).
1993.
Candidiasis. Pathogenesis, diagnosis and treatment, 2nd ed.
Raven Press, New York, N.Y.
|
| 5.
|
Burnie, J. P.,
N. Golbang, and R. C. Matthews.
1997.
Semiquantitative polymerase chain reaction enzyme immunoassay for diagnosis of disseminated candidiasis.
Eur. J. Clin. Microbiol. Infect. Dis.
16:346-350[Medline].
|
| 6.
|
Calderone, R.,
E. Enache,
T. Eskandari,
E. Wadsworth, and J. Sturtevant.
1997.
Adherence of Candida albicans to mammalian cells in vitro: nutritional influences, p. 75-83.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanisms. Salken Publishing Co., Tokyo, Japan.
|
| 7.
|
Calderone, R. A., and P. C. Braun.
1991.
Adherence and receptor relationships of Candida albicans.
Microbiol. Rev.
55:1-20[Abstract/Free Full Text].
|
| 8.
|
Cassone, A.
1989.
Cell wall of Candida albicans: its functions and its impact on the host.
Curr. Top. Med. Mycol.
3:248-314[Medline].
|
| 9.
|
Castro, M.,
N. V. Ralston,
T. I. Morgenthaler,
M. S. Rohrbach, and A. H. Limper.
1994.
Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components.
Infect. Immun.
62:3138-3145[Abstract/Free Full Text].
|
| 10.
|
Daniel, P. F.,
B. Winchester, and C. D. Warren.
1994.
Mammalian alpha-mannosidases multiple forms but a common purpose?
Glycobiology
4:551-566[Abstract/Free Full Text].
|
| 11.
|
De Bernardis, F.,
C. Girmenia,
M. Boccanera,
D. Adriani,
P. Martino, and A. Cassone.
1993.
Use of a monoclonal antibody in a dot immunobinding assay for detection of a circulating mannoprotein of Candida spp. in neutropenic patients with invasive candidiasis.
J. Clin. Microbiol.
31:3142-3146[Abstract/Free Full Text].
|
| 12.
|
Faille, C.,
D. W. Mackenzie,
J. C. Michalski, and D. Poulain.
1992.
Evaluation of an enzyme immunoassay using neoglycolipids constructed from Candida albicans oligomannosides to define the specificity of anti-mannan antibodies.
Eur. J. Clin. Microbiol. Infect. Dis.
11:438-446[Medline].
|
| 13.
|
Faille, C.,
J. Wieruszeski,
G. Lepage,
J. Michalski,
D. Poulain, and G. Strecker.
1991.
1H-NMR spectroscopy of manno-oligosaccharides of the -1,2-linked series released from the phosphopeptidomannan of Candida albicans VW32 (serotype A).
Biochem. Biophys. Res. Commun.
181:1251-1258[Medline].
|
| 14.
|
Field, B.,
D. Knipe, and P. Holley.
1996.
Diagnostic virology, p. 401-430.
In
L.-R. Press (ed.), Field virology, 3rd ed. Lippincott-Raven Press, Philadelphia, Pa.
|
| 15.
|
Flahaut, M.,
D. Sanglard,
M. Monod,
J. Bille, and M. Rossier.
1998.
Rapid detection of Candida albicans in clinical samples by DNA amplification of common regions from C. albicans-secreted aspartic proteinase genes.
J. Clin. Microbiol.
36:395-401[Abstract/Free Full Text].
|
| 16.
|
Fradin, C.,
T. Jouault,
A. Mallet,
J. M. Mallet,
D. Camus,
P. Sinay, and D. Poulain.
1996.
Beta-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage.
J. Leukoc. Biol.
60:81-87[Abstract].
|
| 17.
|
Fukazawa, Y.
1989.
Antigenic structure of Candida albicans. Immunochemical basis of the serologic specificity of the mannans in yeasts.
Immunol. Ser.
47:37-62[Medline].
|
| 18.
|
Gentry, L. O.,
I. D. Wilkinson,
A. S. Lea, and M. F. Price.
1983.
Latex agglutination test for detection of Candida antigen in patients with disseminated disease.
Eur. J. Clin. Microbiol.
2:122-128[Medline].
|
| 19.
|
Han, Y.,
T. Kanbe,
R. Cherniak, and J. E. Cutler.
1997.
Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies.
Infect. Immun.
65:4100-4107[Abstract].
|
| 20.
|
Heidenreich, F., and M. P. Dierich.
1985.
Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b.
Infect. Immun.
50:598-600[Abstract/Free Full Text].
|
| 21.
|
Herent, P.,
D. Stynen,
F. Hernando,
J. Fruit, and D. Poulain.
1992.
Retrospective evaluation of two latex agglutination tests for detection of circulating antigens during invasive candidiasis.
J. Clin. Microbiol.
30:2158-2164[Abstract/Free Full Text].
|
| 22.
|
Jacquinot, P. M.,
Y. Plancke,
B. Sendid,
G. Strecker, and D. Poulain.
1999.
Nature of Candida albicans-derived carbohydrate antigen recognized by a monoclonal antibody in patients sera and distribution over Candida species.
FEMS Microbiol. Lett.
166:131-138.
|
| 23.
|
Jarvis, W. R.
1995.
Epidemiology of nosocomial fungal infections, with emphasis on Candida species.
Clin. Infect. Dis.
20:1526-1530[Medline].
|
| 24.
|
Jones, J. M.
1990.
Laboratory diagnosis of invasive candidiasis.
Clin. Microbiol. Rev.
3:32-45[Abstract/Free Full Text].
|
| 25.
|
Kappe, R., and J. Müller.
1991.
Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens.
J. Clin. Microbiol.
29:1665-1669[Abstract/Free Full Text].
|
| 26.
|
Kitz, D.,
P. Sthal, and J. Little.
1992.
The effect of a mannose binding protein on macrophage interaction with Candida albicans.
Cell. Mol. Biol.
38:407-412[Medline].
|
| 26a.
|
Klis, F.
1994.
Cell wall assembly in yeast.
Yeast
10:851-869[Medline].
|
| 27.
|
Kobayashi, H.,
M. Komido,
M. Watanabe,
K. Matsuda,
M. Suzuki,
T. Ikeda,
H. Oyamada,
N. Shibata, and S. Suzuki.
1994.
Structure of cell wall mannan of Candida kefyr IFO 0586.
Infect. Immun.
62:4425-4431[Abstract/Free Full Text].
|
| 28.
|
Kobayashi, H.,
N. Shibata, and S. Suzuki.
1992.
Evidence for oligomannosyl residues containing both -1,2 and -1,2 linkage as serotype A-specific epitope(s) in mannans of Candida albicans species.
Infect. Immun.
60:2106-2109[Abstract/Free Full Text].
|
| 29.
|
Kohno, S.,
K. Mitsutake,
S. Maesaki,
A. Yasuoka,
T. Miyazaki,
M. Kaku,
H. Koga, and K. Hara.
1993.
An evaluation of serodiagnostic tests in patients with candidemia: beta- glucan, mannan, candida antigen by Cand-Tec and D-arabinitol.
Microbiol. Immunol.
37:207-212[Medline].
|
| 30.
|
Koshi, G.,
A. Viswanathan,
M. Chandy, and P. S. Jairaj.
1987.
Development of a coagglutination (COA) technic to detect Candida antigenemia. I. COA versus Candida isolation.
Am. J. Clin. Pathol.
88:429-435[Medline].
|
| 31.
|
Lemieux, C.,
G. St-Germain,
J. Vincelette,
L. Kaufman, and L. de Repentigny.
1990.
Collaborative evaluation of antigen detection by a commercial latex agglutination test and enzyme immunoassay in the diagnosis of invasive candidiasis.
J. Clin. Microbiol.
28:249-253[Abstract/Free Full Text].
|
| 32.
|
Li, R. K., and J. E. Cutler.
1993.
Chemical definition of an epitope/adhesin molecule on Candida albicans.
J. Biol. Chem.
268:18293-18299[Abstract/Free Full Text].
|
| 33.
|
Marodi, L.,
S. Schreiber,
D. C. Anderson,
R. P. MacDermott,
H. M. Korchak, and R. B. Johnston, Jr.
1993.
Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors.
J. Clin. Investig.
91:2596-2601.
|
| 34.
|
Martinez, J. P.,
M. L. Gil,
J. L. Lopez-Ribot, and W. L. Chaffin.
1998.
Serologic response to cell wall mannoproteins and proteins of Candida albicans.
Clin. Microbiol. Rev.
11:121-141[Abstract/Free Full Text].
|
| 35.
|
Matthews, R.,
J. P. Burnie, and W. Lee.
1991.
The application of epitope mapping in the development of a new serological test for systemic candidiasis.
J. Immunol. Methods
143:73-79[Medline].
|
| 36.
|
Matthews, R.,
S. Hodgetts, and J. Burnie.
1995.
Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis.
J. Infect. Dis.
171:1668-1671[Medline].
|
| 37.
|
Meulemans, L.,
A. Andremont,
F. Meunier,
A. M. Ceuppens,
M. L. Garrigues, and D. Stynen.
1991.
Pastorex Candida, a new latex agglutination test for mannan detection in serum of patients with invasive candidiasis, p. 233-236.
In
E. Tümbay, H. P. R. Seeliger, and Ö. Ang (ed.), Candida and candidamycosis. Plenum Press, New York, N.Y.
|
| 38.
|
Mitsutake, K.,
S. Kohno,
T. Miyazaki,
H. Miyazaki,
S. Maesaki, and H. Koga.
1994.
Detection of Candida enolase antibody in patients with candidiasis.
J. Clin. Lab. Anal.
8:207-210[Medline].
|
| 39.
|
Mitsutake, K.,
T. Miyazaki,
T. Tashiro,
Y. Yamamoto,
H. Kakeya,
T. Otsubo,
S. Kawamura,
M. A. Hossain,
T. Noda,
Y. Hirakata, and S. Kohno.
1996.
Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia.
J. Clin. Microbiol.
34:1918-1921[Abstract].
|
| 40.
|
Miyazaki, T.,
S. Kohno,
K. Mitsutake,
S. Maesaki,
K. Tanaka,
N. Ishikawa, and K. Hara.
1995.
Plasma (1 3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis.
J. Clin. Microbiol.
33:3115-3118[Abstract].
|
| 41.
|
Nelson, R. D.,
N. Shibata,
R. P. Podzorski, and M. J. Herron.
1991.
Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action.
Clin. Microbiol. Rev.
4:1-19[Abstract/Free Full Text].
|
| 42.
|
Obayashi, T.,
M. Yoshida,
T. Mori,
H. Goto,
A. Yasuoka,
H. Iwasaki,
H. Teshima,
S. Kohno,
A. Horiuchi,
A. Ito, et al.
1995.
Plasma (13)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.
Lancet
345:17-20[Medline].
|
| 43.
|
Odds, F. C. (ed.).
1988.
Candida and candidiasis. A review and bibliography.
Baillière Tindall, London, United Kingdom.
|
| 44.
|
Odds, F. C., and G. Evans.
1980.
Distribution of pathogenic yeasts and humoral antibodies to Candida among hospital inpatients.
J. Clin. Pathol.
33:750-756[Abstract/Free Full Text].
|
| 45.
|
Osumi, M.
1998.
The ultrastructure of yeast: cell wall structure and formation.
Micron
29:207-233.
|
| 46.
|
Pittet, D.
1993.
Nosocomial bloodstream infections, p. 512-555.
In
R. P. Wenzel (ed.), Prevention and control of nosocomial infections, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.
|
| 47.
|
Poulain, D.,
C. Faille,
C. Delaunoy,
P. Jacquinot,
P. Trinel, and D. Camus.
1993.
Probable presence of (1-2)-linked oligomannosides that act as human immunoglobulin G3 epitopes and are distributed over a Candida albicans 14- to 18-kilodalton antigen.
Infect. Immun.
61:1164-1166[Abstract/Free Full Text].
|
| 48.
|
Poulain, D.,
T. Jouault, and P. Trinel.
1997.
Immunoreactivity of Candida albicans -1,2-linked oligomannosides and phospholipomannan, p. 175-181.
In
S. Suzuki, and M. Suzuki (ed.), Fungal cells in biodefense mechanisms. Salken Publishing Co., Tokyo, Japan.
|
| 49.
|
Poulain, D., and J. M. Pinon.
1986.
Diagnosis of systemic candidiasis: development of co-counterimmunoelectrophoresis.
Eur. J. Clin. Microbiol.
5:420-426[Medline].
|
| 50.
|
Poulain, D.,
R. Robert,
F. Mesnard,
B. Sendid,
G. Lepage, and D. Camus.
1997.
Clearances of Candida albicans-derived alpha- and beta-linked mannose residues in sera from patients with candidiasis.
Eur. J. Clin. Microbiol. Infect. Dis.
16:16-20[Medline].
|
| 51.
|
Quinton, J. F.,
B. Sendid,
D. Reumaux,
P. Duthilleul,
A. Cortot,
B. Grandbastien,
G. Charrier,
S. Targan,
J. F. Colombel, and D. Poulain.
1998.
Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
Gut
42:788-791[Abstract/Free Full Text].
|
| 52.
|
Reiss, E., and C. J. Morrison.
1993.
Nonculture methods for diagnosis of disseminated candidiasis.
Clin. Microbiol. Rev.
6:311-323[Abstract/Free Full Text].
|
| 53.
|
Reiss, E.,
L. Stockman,
R. J. Kuykendall, and S. J. Smith.
1982.
Dissociation of mannan-serum complexes and detection of Candida albicans mannan by enzyme immunoassay variations.
Clin. Chem.
28:306-310[Abstract/Free Full Text].
|
| 54.
|
Sackett, D. L.,
R. B. Haynes, and P. Tugwell.
1985.
Clinical epidemiology. The interpretation of diagnostic data, p. 59-138.
Little, Brown & Co., Boston, Mass.
|
| 55.
|
Saral, R.
1991.
Candida and Aspergillus infections in immunocompromised patients: an overview.
Rev. Infect. Dis.
13:487-492[Medline].
|
| 56.
|
Shepherd, M. G.
1987.
Cell envelope of Candida albicans.
Crit. Rev. Microbiol.
15:7-25[Medline].
|
| 57.
|
Shibata, N.,
M. Arai,
E. Haga,
T. Kikuchi,
M. Najima,
T. Satoh,
H. Kobayashi, and S. Suzuki.
1992.
Structural identification of an epitope of antigenic factor 5 in mannans of Candida albicans NIH B-792 (serotype B) and J-1012 (serotype A) as -1,2-linked oligomannosyl residues.
Infect. Immun.
60:4100-4110[Abstract/Free Full Text].
|
| 58.
|
Shibata, N.,
K. Hisamichi,
H. Kobayashi, and S. Suzuki.
1993.
Complete assignment of 1H and 13C nuclear magnetic resonance chemical shifts of beta-1,2-linked mannooligosaccharides isolated from the phosphomannan of the pathogenic yeast Candida albicans NIH B-792 strain.
Arch. Biochem. Biophys.
302:113-117[Medline].
|
| 59.
|
Stahl, P. D.
1990.
The macrophage mannose receptor: current status.
Am. J. Respir. Cell. Mol. Biol.
2:317-318.
|
| 60.
|
Summerfield, J. A., and M. E. Taylor.
1986.
Mannose-binding proteins in human serum: identification of mannose-specific immunoglobulins and a calcium-dependent lectin, of broader carbohydrate specificity, secreted by hepatocytes.
Biochim. Biophys. Acta
883:197-206[Medline].
|
| 61.
|
Suzuki, S.
1997.
Immunochemical study on mannans of genus Candida. I. Structural investigation of antigenic factors 1, 4, 5, 6, 8, 9, 11, 13, 13b and 34.
Curr. Top. Med. Mycol.
8:57-70[Medline].
|
| 62.
|
Switchenko, A. C.,
C. G. Miyada,
T. C. Goodman,
T. J. Walsh,
B. Wong,
M. J. Becker, and E. F. Ullman.
1994.
An automated enzymatic method for measurement of D-arabinitol, a metabolite of pathogenic Candida species.
J. Clin. Microbiol.
32:92-97[Abstract/Free Full Text].
|
| 63.
|
Talluri, G.,
C. Mangone,
J. Freyle,
D. Shirazian,
H. Lehman, and G. J. Wise.
1998.
Polymerase chain reaction used to detect candidemia in patients with candiduria.
Urology
51:501-505[Medline].
|
| 64.
|
Trinel, P. A.,
M. Borg-von-Zepelin,
G. Lepage,
T. Jouault,
D. Mackenzie, and D. Poulain.
1993.
Isolation and preliminary characterization of the 14- to 18-kilodalton Candida albicans antigen as a phospholipomannan containing beta-1,2-linked oligomannosides.
Infect. Immun.
61:4398-4405[Abstract/Free Full Text].
|
| 65.
|
Trinel, P. A.,
C. Faille,
P. M. Jacquinot,
J. C. Cailliez, and D. Poulain.
1992.
Mapping of Candida albicans oligomannosidic epitopes by using monoclonal antibodies.
Infect. Immun.
60:3845-3851[Abstract/Free Full Text].
|
| 66.
|
Tsuchiya, T.,
Y. Fukazawa,
M. Taguchi,
T. Kase, and T. Shinoda.
1974.
Serologic aspects on yeast classification.
Mycopathol. Mycol. Appl.
53:77-91[Medline].
|
| 67.
|
Van Deventer, A. J.,
H. Van Vliet,
W. Hop, and W. Goessens.
1994.
Diagnostic value of anti-Candida enolase antibodies.
J. Clin. Microbiol.
32:17-23[Abstract/Free Full Text].
|
| 68.
|
Van Deventer, A. J.,
W. H. Goessens,
J. H. van Zeijl,
J. W. Mouton,
M. F. Michel, and H. A. Verbrugh.
1996.
Kinetics of anti-mannan antibodies useful in confirming invasive candidiasis in immunocompromised patients.
Microbiol. Immunol.
40:125-131[Medline].
|
| 69.
|
Vincent, J. L.,
D. J. Bihari,
P. M. Suter,
H. A. Bruining,
J. White,
M. H. Nicolas-Chanoin,
M. Wolff,
R. C. Spencer, and M. Hemmer.
1995.
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.
JAMA
274:639-644[Abstract/Free Full Text].
|
| 70.
|
Voss, A.,
J. A. Kluytmans,
J. G. Koeleman,
L. Spanjaard,
C. M. Vandenbroucke-Grauls,
H. A. Verbrugh,
M. C. Vos,
A. Y. Weersink,
J. A. Hoogkamp-Korstanje, and J. F. Meis.
1996.
Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.
Eur. J. Clin. Microbiol. Infect. Dis.
15:909-912[Medline].
|
| 71.
|
Walsh, T. J.,
J. W. Hathorn,
J. D. Sobel,
W. G. Merz,
V. Sanchez,
S. M. Maret,
H. R. Buckley,
M. A. Pfaller,
R. Schaufele,
C. Sliva, et al.
1991.
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis.
N. Engl. J. Med.
324:1026-1031[Abstract].
|
| 72.
|
Weiner, M. H., and M. Coats-Stephen.
1979.
Immunodiagnosis of systemic candidiasis: mannan antigenemia detected by radioimmunoassay in experimental and human infections.
J. Infect. Dis.
140:989-993[Medline].
|
| 73.
|
Wenzel, R. P.
1995.
Nosocomial candidemia: risk factors and attributable mortality.
Clin. Infect. Dis.
20:1531-1534[Medline].
|
Journal of Clinical Microbiology, May 1999, p. 1510-1517, Vol. 37, No. 5
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hope, W. W
(2009). Assessing candiduria in a critically ill patient. BMJ
338: b2289-b2289
[Full Text]
-
Ellis, M., Al-Ramadi, B., Bernsen, R., Kristensen, J., Alizadeh, H., Hedstrom, U.
(2009). Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol
58: 606-615
[Abstract]
[Full Text]
-
Sendid, B., Dotan, N., Nseir, S., Savaux, C., Vandewalle, P., Standaert, A., Zerimech, F., Guery, B. P., Dukler, A., Colombel, J. F., Poulain, D.
(2008). Antibodies against Glucan, Chitin, and Saccharomyces cerevisiae Mannan as New Biomarkers of Candida albicans Infection That Complement Tests Based on C. albicans Mannan. CVI
15: 1868-1877
[Abstract]
[Full Text]
-
Clancy, C. J., Nguyen, M.-L., Cheng, S., Huang, H., Fan, G., Jaber, R. A., Wingard, J. R., Cline, C., Nguyen, M. H.
(2008). Immunoglobulin G Responses to a Panel of Candida albicans Antigens as Accurate and Early Markers for the Presence of Systemic Candidiasis. J. Clin. Microbiol.
46: 1647-1654
[Abstract]
[Full Text]
-
Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S., Sulahian, A.
(2008). Contribution of the (1->3)-{beta}-D-Glucan Assay for Diagnosis of Invasive Fungal Infections. J. Clin. Microbiol.
46: 1009-1013
[Abstract]
[Full Text]
-
Hata, D. J., Hall, L., Fothergill, A. W., Larone, D. H., Wengenack, N. L.
(2007). Multicenter Evaluation of the New VITEK 2 Advanced Colorimetric Yeast Identification Card. J. Clin. Microbiol.
45: 1087-1092
[Abstract]
[Full Text]
-
Lain, A., Moragues, M. D., Ruiz, J. C. G., Mendoza, J., Camacho, A., del Palacio, A., Ponton, J.
(2007). Evaluation of a Novel Enzyme-Linked Immunosorbent Assay To Detect Immunoglobulin G Antibody to Enolase for Serodiagnosis of Invasive Candidiasis. CVI
14: 318-319
[Abstract]
[Full Text]
-
Fujita, S.-i., Takamura, T., Nagahara, M., Hashimoto, T.
(2006). Evaluation of a newly developed down-flow immunoassay for detection of serum mannan antigens in patients with candidaemia.. J Med Microbiol
55: 537-543
[Abstract]
[Full Text]
-
Kosonen, J., Rantala, A., Little, C. H., Lintu, P., Harjamaki, P.-R., Georgiou, G. M., Cone, R. E., Savolainen, J.
(2006). Increased Levels of Candida albicans Mannan-Specific T-Cell-Derived Antigen Binding Molecules in Patients with Invasive Candidiasis. CVI
13: 467-474
[Abstract]
[Full Text]
-
White, P. L., Archer, A. E., Barnes, R. A.
(2005). Comparison of Non-Culture-Based Methods for Detection of Systemic Fungal Infections, with an Emphasis on Invasive Candida Infections. J. Clin. Microbiol.
43: 2181-2187
[Abstract]
[Full Text]
-
Masuoka, J.
(2004). Surface Glycans of Candida albicans and Other Pathogenic Fungi: Physiological Roles, Clinical Uses, and Experimental Challenges. Clin. Microbiol. Rev.
17: 281-310
[Abstract]
[Full Text]
-
Verduyn Lunel, F. M., Voss, A., Kuijper, E. J., Gelinck, L. B. S., Hoogerbrugge, P. M., Liem, K. L., Kullberg, B. J., Verweij, P. E.
(2004). Detection of the Candida Antigen Mannan in Cerebrospinal Fluid Specimens from Patients Suspected of Having Candida Meningitis. J. Clin. Microbiol.
42: 867-870
[Abstract]
[Full Text]
-
Girmenia, C., Martino, P., De Bernardis, F., Boccanera, M., Cassone, A.
(2004). Lack of circulating Candida mannoprotein antigen in patients with focal hepatosplenic candidiasis. J Med Microbiol
53: 103-106
[Abstract]
[Full Text]
-
Yera, H, Poulain, D, Lefebvre, A, Camus, D, Sendid, B
(2004). Polymicrobial candidaemia revealed by peripheral blood smear and chromogenic medium. J. Clin. Pathol.
57: 196-198
[Abstract]
[Full Text]
-
Sendid, B., Jouault, T., Coudriau, R., Camus, D., Odds, F., Tabouret, M., Poulain, D.
(2004). Increased Sensitivity of Mannanemia Detection Tests by Joint Detection of {alpha}- and {beta}-Linked Oligomannosides during Experimental and Human Systemic Candidiasis. J. Clin. Microbiol.
42: 164-171
[Abstract]
[Full Text]
-
Sendid, B., Caillot, D., Baccouch-Humbert, B., Klingspor, L., Grandjean, M., Bonnin, A., Poulain, D.
(2003). Contribution of the Platelia Candida-Specific Antibody and Antigen Tests to Early Diagnosis of Systemic Candida tropicalis Infection in Neutropenic Adults. J. Clin. Microbiol.
41: 4551-4558
[Abstract]
[Full Text]
-
Morrison, C. J., Hurst, S. F., Reiss, E.
(2003). Competitive Binding Inhibition Enzyme-Linked Immunosorbent Assay That Uses the Secreted Aspartyl Proteinase of Candida albicans as an Antigenic Marker for Diagnosis of Disseminated Candidiasis. CVI
10: 835-848
[Abstract]
[Full Text]
-
Rimek, D., Singh, J., Kappe, R.
(2003). Cross-Reactivity of the PLATELIA CANDIDA Antigen Detection Enzyme Immunoassay with Fungal Antigen Extracts. J. Clin. Microbiol.
41: 3395-3398
[Abstract]
[Full Text]
-
Dromer, F., Chevalier, R., Sendid, B., Improvisi, L., Jouault, T., Robert, R., Mallet, J. M., Poulain, D.
(2002). Synthetic Analogues of {beta}-1,2 Oligomannosides Prevent Intestinal Colonization by the Pathogenic Yeast Candida albicans. Antimicrob. Agents Chemother.
46: 3869-3876
[Abstract]
[Full Text]
-
Yeo, S. F., Wong, B.
(2002). Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections. Clin. Microbiol. Rev.
15: 465-484
[Abstract]
[Full Text]
-
SENDID, B., POIROT, J. L., TABOURET, M., BONNIN, A., CAILLOT, D., CAMUS, D., POULAIN, D.
(2002). Combined detection of mannanaemia and anti-mannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol
51: 433-442
[Abstract]
[Full Text]
-
Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., Villard, O., Liu, K.-L., Natarajan-Ame, S., Lutz, P., Dufour, P., Bergerat, J.-P., Candolfi, E.
(2002). AspergillusGalactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients. JCO
20: 1898-1906
[Abstract]
[Full Text]
Top
Abstract
Introduction
